{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:32:10Z","timestamp":1789475530817,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40263-025-01219-y","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T06:04:37Z","timestamp":1756620277000},"page":"1071-1082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Brexpiprazole for the Treatment of Agitation in Older Adults with Alzheimer\u2019s Disease: A Systematic Review, Bayesian Meta-analysis, and Meta-regression"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4789-6019","authenticated-orcid":false,"given":"Anderson Matheus Pereira","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ocilio","family":"Ribeiro Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe","family":"Virgilio Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Lucas","family":"Machado Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Lee Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"\u0141ajczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Let\u00edcia de Bastos Maximiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Cal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eryvelton","family":"de Souza Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Bernadete","family":"de Sousa Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"1219_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h369","volume":"350","author":"HC Kales","year":"2015","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350: h369. https:\/\/doi.org\/10.1136\/bmj.h369.","journal-title":"BMJ"},{"issue":"1","key":"1219_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/S1041610214001963","volume":"27","author":"J Cummings","year":"2015","unstructured":"Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27(1):7\u201317. https:\/\/doi.org\/10.1017\/S1041610214001963.","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"1219_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1192\/bjp.bp.113.128710","volume":"205","author":"C Ballard","year":"2014","unstructured":"Ballard C, Corbett A, Howard R. Prescription of antipsychotics in people with dementia. Br J Psychiatry. 2014;205(1):4\u20135. https:\/\/doi.org\/10.1192\/bjp.bp.113.128710.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"1219_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1176\/appi.focus.15107","volume":"15","author":"VI Reus","year":"2017","unstructured":"Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Focus (Am Psychiatr Publ). 2017;15(1):81\u20134. https:\/\/doi.org\/10.1176\/appi.focus.15107.","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"suppl_1","key":"1219_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/geront\/gnx182","volume":"58","author":"S Fazio","year":"2018","unstructured":"Fazio S, Pace D, Maslow K, Zimmerman S, Kallmyer B. Alzheimer\u2019s association dementia care practice recommendations. Gerontologist. 2018;58(suppl_1):S1\u20139. https:\/\/doi.org\/10.1093\/geront\/gnx182.","journal-title":"Gerontologist"},{"issue":"6","key":"1219_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/14656566.2023.2195539","volume":"24","author":"D Lee","year":"2023","unstructured":"Lee D, Clark ED, Antonsdottir IM, Porsteinsson AP. A 2023 update on the advancements in the treatment of agitation in Alzheimer\u2019s disease. Expert Opin Pharmacother. 2023;24(6):691\u2013703. https:\/\/doi.org\/10.1080\/14656566.2023.2195539.","journal-title":"Expert Opin Pharmacother"},{"key":"1219_CR7","unstructured":"Administration USFaD. FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer\u2019s disease. 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease. Accessed 27 Mar 2025."},{"issue":"4","key":"1219_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","volume":"28","author":"GT Grossberg","year":"2020","unstructured":"Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2020;28(4):383\u2013400. https:\/\/doi.org\/10.1016\/j.jagp.2019.09.009.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"1219_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3233\/JAD-240491","volume":"102","author":"S Behl","year":"2024","unstructured":"Behl S, Slomkowski M, Chen D, Chang D, Hefting N, Lee D, et al. Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer\u2019s disease: a 12-week, active-treatment, extension trial. J Alzheimers Dis. 2024;102(2):520\u20139. https:\/\/doi.org\/10.3233\/JAD-240491.","journal-title":"J Alzheimers Dis"},{"issue":"22","key":"1219_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa052827","volume":"353","author":"PS Wang","year":"2005","unstructured":"Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335\u201341. https:\/\/doi.org\/10.1056\/NEJMoa052827.","journal-title":"N Engl J Med"},{"issue":"3","key":"1219_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","volume":"14","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191\u2013210. https:\/\/doi.org\/10.1097\/01.JGP.0000200589.01396.6d.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1219_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076268","volume":"385","author":"PLH Mok","year":"2024","unstructured":"Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ. 2024;385: e076268. https:\/\/doi.org\/10.1136\/bmj-2023-076268.","journal-title":"BMJ"},{"issue":"2","key":"1219_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2165\/00023210-200519020-00001","volume":"19","author":"N Herrmann","year":"2005","unstructured":"Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19(2):91\u2013103. https:\/\/doi.org\/10.2165\/00023210-200519020-00001.","journal-title":"CNS Drugs"},{"issue":"10","key":"1219_CR14","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1007\/s10072-024-07576-8","volume":"45","author":"G Marinheiro","year":"2024","unstructured":"Marinheiro G, Dantas JM, Mutarelli A, Menegaz de Almeida A, Monteiro GA, Zerlotto DS, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials. Neurol Sci. 2024;45(10):4679\u201386. https:\/\/doi.org\/10.1007\/s10072-024-07576-8.","journal-title":"Neurol Sci"},{"issue":"11","key":"1219_CR15","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1002\/alz.14282","volume":"20","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Adachi J, Hirota N, Iba K, Shimizu K, Nakai M, et al. Brexpiprazole treatment for agitation in Alzheimer\u2019s dementia: a randomized study. Alzheimers Dement. 2024;20(11):8002\u201311. https:\/\/doi.org\/10.1002\/alz.14282.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1219_CR16","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jagp.2024.11.003","volume":"33","author":"VM Aga","year":"2025","unstructured":"Aga VM. Brexpiprazole for the treatment of agitation in Alzheimer\u2019s disease dementia: clinical uncertainties and the path forward. Am J Geriatr Psychiatry. 2025;33(3):322\u20139. https:\/\/doi.org\/10.1016\/j.jagp.2024.11.003.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1219_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPTTJ Higgins","year":"2019","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 1st ed. New York: Wiley; 2019. https:\/\/doi.org\/10.1002\/9781119536604.","edition":"1"},{"key":"1219_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"issue":"7","key":"1219_CR19","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology. 1984;34(7):939\u201344. https:\/\/doi.org\/10.1212\/wnl.34.7.939.","journal-title":"Neurology"},{"key":"1219_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"Suppl 2","key":"1219_CR21","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/00002093-199700112-00007","volume":"11","author":"E Koss","year":"1997","unstructured":"Koss E, Weiner M, Ernesto C, Cohen-Mansfield J, Ferris SH, Grundman M, et al. Assessing patterns of agitation in Alzheimer\u2019s disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer\u2019s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S45\u201350. https:\/\/doi.org\/10.1097\/00002093-199700112-00007.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"7","key":"1219_CR22","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"issue":"2","key":"1219_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1532-5415.1998.tb02542.x","volume":"46","author":"DI Kaufer","year":"1998","unstructured":"Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer\u2019s disease: the neuropsychiatric inventory caregiver distress scale. J Am Geriatr Soc. 1998;46(2):210\u20135. https:\/\/doi.org\/10.1111\/j.1532-5415.1998.tb02542.x.","journal-title":"J Am Geriatr Soc"},{"key":"1219_CR24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672\u20136. https:\/\/doi.org\/10.1192\/bjp.154.5.672.","journal-title":"Br J Psychiatry"},{"key":"1219_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970. https:\/\/doi.org\/10.1111\/j.1600-0447.1970.tb02066.x.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"1","key":"1219_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55\u201379. https:\/\/doi.org\/10.1002\/jrsm.1164.","journal-title":"Res Synth Methods"},{"key":"1219_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF. The hartung-knapp-sidik-jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard dersimonian-laird method. BMC Med Res Methodol. 2014;14:25. https:\/\/doi.org\/10.1186\/1471-2288-14-25.","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"1219_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"1","key":"1219_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jclinepi.2014.08.012","volume":"68","author":"KM Rhodes","year":"2015","unstructured":"Rhodes KM, Turner RM, Higgins JP. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol. 2015;68(1):52\u201360. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.08.012.","journal-title":"J Clin Epidemiol"},{"key":"1219_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2022.107303","volume":"229","author":"C Rover","year":"2023","unstructured":"Rover C, Friede T. Using the bayesmeta R package for Bayesian random-effects meta-regression. Comput Methods Programs Biomed. 2023;229: 107303. https:\/\/doi.org\/10.1016\/j.cmpb.2022.107303.","journal-title":"Comput Methods Programs Biomed"},{"issue":"4","key":"1219_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"issue":"12","key":"1219_CR32","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","volume":"80","author":"D Lee","year":"2023","unstructured":"Lee D, Slomkowski M, Hefting N, Chen D, Larsen KG, Kohegyi E, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80(12):1307\u201316. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3810.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1219_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70099","volume":"11","author":"KY Liu","year":"2025","unstructured":"Liu KY, Ivenso C, Howard R, Rapaport P, Reeves S, Banerjee S, et al. Three approaches to determining clinically meaningful benefit on the Cohen-Mansfield agitation inventory in dementia clinical trials for agitation. Alzheimers Dement (N Y). 2025;11(2): e70099. https:\/\/doi.org\/10.1002\/trc2.70099.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"12","key":"1219_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013304.pub2","volume":"12","author":"V Muhlbauer","year":"2021","unstructured":"Muhlbauer V, Mohler R, Dichter MN, Zuidema SU, Kopke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia. Cochrane Database Syst Rev. 2021;12(12): CD013304. https:\/\/doi.org\/10.1002\/14651858.CD013304.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1219_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jnnp-2014-308112","volume":"86","author":"J Wang","year":"2015","unstructured":"Wang J, Yu JT, Wang HF, Meng XF, Wang C, Tan CC, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(1):101\u20139. https:\/\/doi.org\/10.1136\/jnnp-2014-308112.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"1219_CR36","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","volume":"168","author":"CL Vigen","year":"2011","unstructured":"Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer\u2019s disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.2011.08121844.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1219_CR37","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamainternmed.2014.6930","volume":"175","author":"LA Fraser","year":"2015","unstructured":"Fraser LA, Liu K, Naylor KL, Hwang YJ, Dixon SN, Shariff SZ, et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. JAMA Intern Med. 2015;175(3):450\u20132. https:\/\/doi.org\/10.1001\/jamainternmed.2014.6930.","journal-title":"JAMA Intern Med"},{"issue":"Suppl 2","key":"1219_CR38","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","volume":"25","author":"CU Correll","year":"2010","unstructured":"Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(Suppl 2):S12\u201321. https:\/\/doi.org\/10.1016\/S0924-9338(10)71701-6.","journal-title":"Eur Psychiatry"},{"issue":"7","key":"1219_CR39","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682\u201391. https:\/\/doi.org\/10.1001\/jama.2014.93.","journal-title":"JAMA"},{"issue":"3","key":"1219_CR40","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589\u2013604. https:\/\/doi.org\/10.1124\/jpet.114.213793.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1219_CR41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1124\/jpet.114.213819","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605\u201314. https:\/\/doi.org\/10.1124\/jpet.114.213819.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1219_CR42","first-page":"184","volume":"19","author":"P Presecki","year":"2007","unstructured":"Presecki P, Mimica N. Involuntary emotional expression disorder\u2014new\/old disease in psychiatry and neurology. Psychiatr Danub. 2007;19(3):184\u20138.","journal-title":"Psychiatr Danub"},{"key":"1219_CR43","doi-asserted-by":"publisher","unstructured":"By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2019 updated AGS Beers criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674\u201394. https:\/\/doi.org\/10.1111\/jgs.15767.","DOI":"10.1111\/jgs.15767"},{"key":"1219_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2024.105521","volume":"126","author":"Y Yoshida","year":"2024","unstructured":"Yoshida Y, Ishizaki T, Masui Y, Miura Y, Matsumoto K, Nakagawa T, et al. Effects of multimorbidity and polypharmacy on physical function in community-dwelling older adults: a 3-year prospective cohort study from the SONIC. Arch Gerontol Geriatr. 2024;126: 105521. https:\/\/doi.org\/10.1016\/j.archger.2024.105521.","journal-title":"Arch Gerontol Geriatr"},{"issue":"1","key":"1219_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/clpt.2008.224","volume":"85","author":"SN Hilmer","year":"2009","unstructured":"Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85(1):86\u20138. https:\/\/doi.org\/10.1038\/clpt.2008.224.","journal-title":"Clin Pharmacol Ther"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01219-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01219-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01219-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:04:26Z","timestamp":1760173466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01219-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1219"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01219-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"A.M.P.S., L.F., O.R.G., F.V.R., and P.L.M.M. drafted the initial version of the manuscript. A.M.P.S., M.B.S.M., L.F., and E.S.F. conceived the study, designed the methodology, and ensured its validation. A.M.P.S., L.F., M.L.H., and E.S.F. performed data extraction and statistical analyses. M.B.S.M., M.L.M., H.C., and P.\u0141. conducted the risk-of-bias and methodological quality assessments. M.B.S.M., P.\u0141., and H.C. supervised the project and critically revised the final manuscript. All authors contributed to the interpretation of the results and approved the final version of the manuscript. A.M.P.S. assumes full responsibility for the study, including its conception, access to data, and the decision to submit the manuscript for publication. All authors had full access to the data and accept responsibility for the submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}